Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world.

World J Gastroenterol · 2023 · PMC10701330 · PMID 38077159

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Our study found that low baseline NLR, dNLR and PLR showed a trend for OS benefit, but a statistically significant difference was not observed.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.